EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma
<i>Background:</i> To evaluate whether EQD2<sub>(α/β = 3Gy)</sub> at 2 cm<sup>3</sup> of the most exposed area of the vagina is related to late vaginal toxicity in postoperative endometrial cancer (PEC) patients (p) treated with exclusive brachytherapy (BT). <i...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/10/3059 |
| _version_ | 1797550362539851776 |
|---|---|
| author | Yaowen Zhang Balbino Fornes Gabriela Gómez Irene Bentoldrà Clara Carmona Antonio Herreros Sebastià Sabater Inmaculada Nicolás Yan Li Joan Sánchez Albert Biete Aureli Torné Carlos Ascaso Ángeles Rovirosa |
| author_facet | Yaowen Zhang Balbino Fornes Gabriela Gómez Irene Bentoldrà Clara Carmona Antonio Herreros Sebastià Sabater Inmaculada Nicolás Yan Li Joan Sánchez Albert Biete Aureli Torné Carlos Ascaso Ángeles Rovirosa |
| author_sort | Yaowen Zhang |
| collection | DOAJ |
| description | <i>Background:</i> To evaluate whether EQD2<sub>(α/β = 3Gy)</sub> at 2 cm<sup>3</sup> of the most exposed area of the vagina is related to late vaginal toxicity in postoperative endometrial cancer (PEC) patients (p) treated with exclusive brachytherapy (BT). <i>Methods:</i> From 2014 to 2017, 43p were included in this study. BT was administered: 3-fractions of 6Gy in 37p and 2-fractions of 7.5Gy in 6p. The dose was prescribed at a depth of 5 mm from the applicator surface with dose-point optimization based on distance. The active treatment length was 2.5 cm. CTV-D90 and the dose to the most exposed 2 cm<sup>3</sup> of the vagina was calculated for each patient. Late toxicity of the bladder and rectum was assessed using Radiation Therapy Oncology Group (RTOG) criteria, and vaginal toxicity by objective Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA) (LENT-SOMA) criteria. Statistics: frequency tables, mean, median, range, standard deviation, and box plot. <i>Results:</i> The median follow-up was 51 months (12–68). 20 p (46.5%) and 2 p (4.7%) developed G1 and G2 vaginal complications, respectively. Only 1/2 p-G2 receiving EQD2<sub>(α/β = 3Gy)</sub> at 2 cm<sup>3</sup> >68Gy presented vaginal shortening and 18/20 p-G1 received doses < 68Gy. <i>Conclusions:</i> PECp receiving exclusive brachytherapy with doses < 68Gy EQD2<sub>(α/β = 3Gy)</sub> at 2 cm<sup>2</sup> of the vagina presented only G0–G1 vaginal toxicity, except for one with bleeding telangiectasias. Larger prospective studies are necessary to confirm the present results. |
| first_indexed | 2024-03-10T15:28:08Z |
| format | Article |
| id | doaj.art-025cd4e382e14cb38e1a0d28e416a417 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T15:28:08Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-025cd4e382e14cb38e1a0d28e416a4172023-11-20T17:48:52ZengMDPI AGCancers2072-66942020-10-011210305910.3390/cancers12103059EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial CarcinomaYaowen Zhang0Balbino Fornes1Gabriela Gómez2Irene Bentoldrà3Clara Carmona4Antonio Herreros5Sebastià Sabater6Inmaculada Nicolás7Yan Li8Joan Sánchez9Albert Biete10Aureli Torné11Carlos Ascaso12Ángeles Rovirosa13Fonaments Clinics Department, University of Barcelona, 08036 Barcelona, SpainFonaments Clinics Department, University of Barcelona, 08036 Barcelona, SpainRadiation Oncology Department, Hospital Ángeles Chihuahua, 31217 Chihuahua, MexicoFonaments Clinics Department, University of Barcelona, 08036 Barcelona, SpainFonaments Clinics Department, University of Barcelona, 08036 Barcelona, SpainFonaments Clinics Department, University of Barcelona, 08036 Barcelona, SpainRadiation Oncology Department, Hospital General Universitario de Albacete, 02006 Albacete, SpainGynecologic Cancer Unit, Hospital Clínic Unversitari, 08036 Barcelona, SpainFonaments Clinics Department, University of Barcelona, 08036 Barcelona, SpainEconomics Department, Hospital Clínic Universitari, 08036 Barcelona, SpainFonaments Clinics Department, University of Barcelona, 08036 Barcelona, SpainGynecologic Cancer Unit, Hospital Clínic Unversitari, 08036 Barcelona, SpainFonaments Clinics Department, University of Barcelona, 08036 Barcelona, SpainFonaments Clinics Department, University of Barcelona, 08036 Barcelona, Spain<i>Background:</i> To evaluate whether EQD2<sub>(α/β = 3Gy)</sub> at 2 cm<sup>3</sup> of the most exposed area of the vagina is related to late vaginal toxicity in postoperative endometrial cancer (PEC) patients (p) treated with exclusive brachytherapy (BT). <i>Methods:</i> From 2014 to 2017, 43p were included in this study. BT was administered: 3-fractions of 6Gy in 37p and 2-fractions of 7.5Gy in 6p. The dose was prescribed at a depth of 5 mm from the applicator surface with dose-point optimization based on distance. The active treatment length was 2.5 cm. CTV-D90 and the dose to the most exposed 2 cm<sup>3</sup> of the vagina was calculated for each patient. Late toxicity of the bladder and rectum was assessed using Radiation Therapy Oncology Group (RTOG) criteria, and vaginal toxicity by objective Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA) (LENT-SOMA) criteria. Statistics: frequency tables, mean, median, range, standard deviation, and box plot. <i>Results:</i> The median follow-up was 51 months (12–68). 20 p (46.5%) and 2 p (4.7%) developed G1 and G2 vaginal complications, respectively. Only 1/2 p-G2 receiving EQD2<sub>(α/β = 3Gy)</sub> at 2 cm<sup>3</sup> >68Gy presented vaginal shortening and 18/20 p-G1 received doses < 68Gy. <i>Conclusions:</i> PECp receiving exclusive brachytherapy with doses < 68Gy EQD2<sub>(α/β = 3Gy)</sub> at 2 cm<sup>2</sup> of the vagina presented only G0–G1 vaginal toxicity, except for one with bleeding telangiectasias. Larger prospective studies are necessary to confirm the present results.https://www.mdpi.com/2072-6694/12/10/3059endometrial carcinomavaginal toxicityvaginal dosebrachytherapy |
| spellingShingle | Yaowen Zhang Balbino Fornes Gabriela Gómez Irene Bentoldrà Clara Carmona Antonio Herreros Sebastià Sabater Inmaculada Nicolás Yan Li Joan Sánchez Albert Biete Aureli Torné Carlos Ascaso Ángeles Rovirosa EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma Cancers endometrial carcinoma vaginal toxicity vaginal dose brachytherapy |
| title | EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma |
| title_full | EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma |
| title_fullStr | EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma |
| title_full_unstemmed | EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma |
| title_short | EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma |
| title_sort | eqd2 analyses of vaginal complications in exclusive brachytherapy for postoperative endometrial carcinoma |
| topic | endometrial carcinoma vaginal toxicity vaginal dose brachytherapy |
| url | https://www.mdpi.com/2072-6694/12/10/3059 |
| work_keys_str_mv | AT yaowenzhang eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT balbinofornes eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT gabrielagomez eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT irenebentoldra eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT claracarmona eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT antonioherreros eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT sebastiasabater eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT inmaculadanicolas eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT yanli eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT joansanchez eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT albertbiete eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT aurelitorne eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT carlosascaso eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma AT angelesrovirosa eqd2analysesofvaginalcomplicationsinexclusivebrachytherapyforpostoperativeendometrialcarcinoma |